Practice Management

Top Story

IRIS: Pioglitazone prevents secondary CV events in high-risk patients

September 18, 2017

Nondiabetic, insulin-resistant patients at elevated risk for stroke or MI derive a greater benefit from pioglitazone compared with those at lower risk, but fracture risk is also higher, according to a secondary analysis of data from the IRIS trial.

Walter N. Kernan, MD, professor of medicine at Yale School of Medicine, and colleagues enrolled 3,876 participants (mean age, 63 years) with qualifying ischemic stroke or transient ischemic attack within 180 days of entry with insulin resistance but without type 1 or type 2 diabetes from February 2005 to January 2013.

AADE: Telehealth should be included in Medicare Diabetes Prevention Program

September 18, 2017
The American Association of Diabetes Educators outlined several recommendations for a CMS proposal to include the Medicare Diabetes Prevention Program in the 2018…

WHO drafts global exercise action plan

September 17, 2017
WHO has released a draft of the Global Action Plan on Physical Activity for 2018 to 2030 to address the many health concerns associated with inactivity, according to a…

Gene therapy via skin could treat obesity, type 2 diabetes

September 16, 2017
In a proof-of-concept study, gene therapy administered through skin transplants showed promise as an avenue for treating type 2 diabetes and obesity, according to a…
More Headlines »
CME

Practical Lipidology® Volume 4, Number 1: Focus on LDL Reduction and PCSK9 Inhibition

This activity is supported by an educational grant from Amgen

A preponderance of data shows that low-density lipoprotein cholesterol (LDL-C) plays a causal role in atherosclerotic…
More »
Video
Meeting News

VIDEO: Screening BMD crucial to diagnose fracture risk

May 3, 2017
More »
Resource Centers
CNE CME CPE

What You Need to Know About Familial Chylomicronemia Syndrome: Pathophysiology, Diagnosis, Management, and the Patient Perspective

This activity is supported by an educational grant from Akcea Therapeutics™ A Subsidiary of Ionis Pharmaceuticals, Inc.
Endorsed by: The National Lipid Association.

Familial chylomicronemia syndrome (FCS) is a rare genetic disease that leads to severe hypertriglyceridemia and…
More »
Advertisement
Advertisement